<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11821">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541970</url>
  </required_header>
  <id_info>
    <org_study_id>110659</org_study_id>
    <nct_id>NCT00541970</nct_id>
  </id_info>
  <brief_title>Partially Blind Study to Evaluate Immunogenicity &amp; Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs</brief_title>
  <official_title>Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Papillomavirus (HPV) infection has been established as a necessary cause of cervical
      cancer. GlaxoSmithKline (GSK) Biologicals has developed an HPV vaccine (580299) which
      targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in approximately
      70% of all cervical cancers. In previous trials this vaccine has been found to be
      efficacious in the prevention of incident and persistent HPV-16/18 infections and associated
      cytological abnormalities and cervical dysplasia. In this partially-blind study, GSK
      Biologicals will evaluate the safety and immunogenicity of the HPV vaccine using an
      alternative schedule and an alternative dosing when administered in healthy young females
      aged 9 to 25 years, as compared to the standard HPV vaccine. The Protocol Posting has been
      updated in order to comply with the FDA Amendment Act, Sep 2007. The protocol posting has
      been updated following a protocol amendment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>One month after vaccination with the last dose of the Cervarix vaccine (Cervarix 1/Placebo Group: Month 3; Other groups: Month 7).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Report of Any, and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within 7 days (Day 0-6) after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling larger than (&gt;) 50 millimeters (mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within 7 days (Day 0-6) after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever (defined as axillary temperature equal or above (≥) 37.5 degrees Celsius (°C), gastrointestinal symptoms, which included nausea, vomiting, diarrhoea and/or abdominal pain, headache, myalgia, rash and urticaria. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature ≥ 39 °C. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Related symptom = symptom assessed by the investigator to be causally related to vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies .</measure>
    <time_frame>At Month 3, 1 month after the second dose of vaccine or placebo</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The analysis was performed on the subjects who were administered a 2-dose vaccination schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 7, 1 month after the last dose of vaccine or placebo.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). Groups were stratified into 3 age strata: 9-14, 15-19 and 20-25 years of age at the time of first vaccination. The 15-19 years age stratum in the group receiving the Cervarix vaccine on a 3-dose vaccination schedule was considered an active comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 12, at Month 18, at Month 24, at Month 36, and at Month 48 during the safety follow-up phase.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 7, 1 month after the last dose of vaccine or placebo.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents BAS results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range.This outcome presents CREA results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents EOS results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents Hct results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents ALT results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents LYM results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents MON results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents NEU results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents RBC results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents WBC results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</measure>
    <time_frame>At Month 7 (M7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents PLA results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against Human Papillomavirus 16 (HPV-16) and Human Papillomavirus 18 (HPV-18)</measure>
    <time_frame>At Month 12, at Month 18, at Month 24, at Month 36, and at Month 48 during the safety follow-up phase.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of antibodies (i.e.titers greater than or equal to (≥) cut-off value) in the serum of subjects seronegative before vaccination. Assay cut-off was defined as ≥ 8 ELISA units per milliliter (EL.U/mL) for HPV-16, and 7 EL.U/mL for HPV-18. Seronegative subjects are subjects who had an antibody concentration below cut-off value. Cut-off values were 8 EL.U/mL for antibody concentrations against HPV-16, and 7 EL.U/mL for antibody concentrations against HPV-18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 60 of the safety follow-up phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The assay cut-off for Month 60 was defined as ≥ 19 ELISA units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against Human Papillomavirus 16 (HPV-16) and Human Papillomavirus 18 (HPV-18)</measure>
    <time_frame>At Month 60 of the safety follow-up phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of antibodies (i.e. titers greater than or equal to (≥) cut-off value) in the serum of subjects seronegative before vaccination. Assay cut-off was defined as ≥ 19 ELISA units per milliliter (EL.U/mL). Seronegative subjects are subjects who had an antibody concentration below cut-off value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancy Outcomes.</measure>
    <time_frame>From Month 0 to Month 48.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pregnancy outcomes were ectopic pregnancy, elective termination with no apparent congenital anomaly (ACA), elective termination with congenital anomaly (CA), lost to follow up, pregnancy ongoing, spontaneous abortion with no ACA and live infant with no ACA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancy Outcomes.</measure>
    <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pregnancy outcomes were ectopic pregnancy, elective termination with no apparent congenital anomaly (ACA), elective termination with congenital anomaly (CA), lost to follow up, pregnancy ongoing, spontaneous abortion with no ACA and live infant with no ACA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>Within 30 days (Day 0-29) after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited adverse event (AE) is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = an event that prevented normal activity. Related = an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs).</measure>
    <time_frame>From Month 0 to Month 7.</time_frame>
    <safety_issue>No</safety_issue>
    <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs).</measure>
    <time_frame>From Month 0 to Month 48.</time_frame>
    <safety_issue>No</safety_issue>
    <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs).</measure>
    <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Autoimmune Diseases (NOADs)</measure>
    <time_frame>From Month 0 to Month 7.</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Autoimune Diseases (NOADs)</measure>
    <time_frame>From Month 0 to Month 48.</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Autoimmune Diseases (NOADs)</measure>
    <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</measure>
    <time_frame>From Month 0 to Month 7.</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</measure>
    <time_frame>From Month 0 to Month 48.</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</measure>
    <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs).</measure>
    <time_frame>From Month 0 to Month 7.</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity, or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs).</measure>
    <time_frame>From Month 0 to Month 48.</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">961</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix 1/Placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 1/Placebo/Cervarix 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 2/Placebo/Cervarix 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix</intervention_name>
    <description>Intramuscular injection, different dosing /schedule</description>
    <arm_group_label>Cervarix 1/Placebo Group</arm_group_label>
    <arm_group_label>Cervarix 2/Placebo/Cervarix 2 Group</arm_group_label>
    <arm_group_label>Cervarix 1/Placebo/Cervarix 1 Group</arm_group_label>
    <arm_group_label>Cervarix 2 Group</arm_group_label>
    <other_name>GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) vaccine 580299</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection, different dosing /schedule</description>
    <arm_group_label>Cervarix 1/Placebo Group</arm_group_label>
    <arm_group_label>Cervarix 2/Placebo/Cervarix 2 Group</arm_group_label>
    <arm_group_label>Cervarix 1/Placebo/Cervarix 1 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parents can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  A female subject between, and including, 9 and 25 years of age at the time of the
             first vaccination.

          -  Written informed consent/assent obtained from the subject prior to enrolment. For
             subjects above the legal age of consent, written informed consent must be obtained
             from the subject. For subjects below the legal age of consent, written informed
             consent from the subject's parents/legally acceptable representative, and written
             informed assent must be obtained from the subject.

          -  Healthy subjects as established by medical history and history-oriented clinical
             examination before entering into the study.

          -  Subject must be of non-childbearing potential, or if she is of childbearing
             potential, she must practice adequate contraception for 30 days prior to vaccination,
             have a negative pregnancy test and continue such precautions for two months after
             completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine, or planned
             use during the study period (up to Month 24).

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Concurrently participating in another clinical study, at any time during the study
             period (up to Month 24), in which the subject has been or will be exposed to an
             investigational or a non-investigational product (pharmaceutical product or device).

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after the first dose of vaccine. Planned
             administration/administration of routine vaccines, up to 8 days before the first dose
             of study vaccine is allowed. Enrolment will be deferred until the subject is outside
             of specified window.

          -  Pregnant or breastfeeding female.

          -  A woman planning to become pregnant or planning to discontinue contraceptive
             precautions during the study period, up to two months after the last vaccine dose.

          -  Previous vaccination against HPV or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period (up to Month 24).

          -  Previous administration of components of the investigational vaccine.

          -  Cancer or autoimmune disease under treatment.

          -  Any medically diagnosed or suspected immunosuppressive or immunodeficient condition,
             based on medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Hypersensitivity to latex.

          -  Acute disease at the time of enrolment.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory tests.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period (up to Month 24).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langley</city>
        <state>British Columbia</state>
        <zip>V3A 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rheinstetten</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauberbischofsheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>97941</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weilheim</city>
        <state>Bayern</state>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfenbuettel</city>
        <state>Niedersachsen</state>
        <zip>38302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nordhausen</city>
        <state>Thueringen</state>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011 Dec;7(12):1374-86. doi: 10.4161/hv.7.12.18322. Epub 2011 Dec 1.</citation>
    <PMID>22048171</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>October 29, 2015</lastchanged_date>
  <firstreceived_date>October 9, 2007</firstreceived_date>
  <firstreceived_results_date>October 18, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>viral infections</keyword>
  <keyword>Human Papillomavirus (HPV) vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>cervical cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study included two phases, an active vaccination phase (Months 0-7) followed by a safety follow-up phase (up to the end of the study at Month 60).</recruitment_details>
      <pre_assignment_details>The study was run in an open manner for subjects in the groups receiving the Cervarix vaccine on a 3-dose vaccination schedule. For subjects in the group receiving the Cervarix vaccine on a 2-dose vaccination schedule, the study was run in an observer-blind manner until Month 24, and then in an open manner.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix 1/Placebo Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Cervarix 2 Group</title>
          <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Month 7</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="229"/>
                <participants group_id="P4" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="219"/>
                <participants group_id="P4" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 18</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="215"/>
                <participants group_id="P4" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="208"/>
                <participants group_id="P4" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 36</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="175"/>
                <participants group_id="P3" count="174"/>
                <participants group_id="P4" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 60</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix 1/Placebo Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Cervarix 2 Group</title>
          <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="240"/>
                <measurement group_id="B2" value="241"/>
                <measurement group_id="B3" value="240"/>
                <measurement group_id="B4" value="239"/>
                <measurement group_id="B5" value="960"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17.1" spread="4.30"/>
                <measurement group_id="B2" value="17.2" spread="4.30"/>
                <measurement group_id="B3" value="17.3" spread="4.25"/>
                <measurement group_id="B4" value="17.2" spread="4.38"/>
                <measurement group_id="B5" value="17.2" spread="4.31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="240"/>
                <measurement group_id="B2" value="241"/>
                <measurement group_id="B3" value="240"/>
                <measurement group_id="B4" value="239"/>
                <measurement group_id="B5" value="960"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>One month after vaccination with the last dose of the Cervarix vaccine (Cervarix 1/Placebo Group: Month 3; Other groups: Month 7).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="206"/>
                  <measurement group_id="O3" value="204"/>
                  <measurement group_id="O4" value="208"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [N=224;204;204;208]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5844.6" lower_limit="5259.6" upper_limit="6494.7"/>
                  <measurement group_id="O2" value="10500.9" lower_limit="9356.9" upper_limit="11784.8"/>
                  <measurement group_id="O3" value="7741.6" lower_limit="6868.2" upper_limit="8726.1"/>
                  <measurement group_id="O4" value="13045.3" lower_limit="11211.4" upper_limit="15179.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [N=223;206;204;208]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3543.2" lower_limit="3126.6" upper_limit="4015.3"/>
                  <measurement group_id="O2" value="5997.5" lower_limit="5310.9" upper_limit="6772.8"/>
                  <measurement group_id="O3" value="4811.4" lower_limit="4282.7" upper_limit="5405.3"/>
                  <measurement group_id="O4" value="5087.1" lower_limit="4460.2" upper_limit="5802.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Report of Any, and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling larger than (&gt;) 50 millimeters (mm).</description>
        <time_frame>Within 7 days (Day 0-6) after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="239"/>
                  <measurement group_id="O3" value="238"/>
                  <measurement group_id="O4" value="238"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Report of Any, and Grade 3 Solicited Local Symptoms</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling larger than (&gt;) 50 millimeters (mm).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="222"/>
                  <measurement group_id="O2" value="225"/>
                  <measurement group_id="O3" value="222"/>
                  <measurement group_id="O4" value="225"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="123"/>
                  <measurement group_id="O4" value="145"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness &gt; 50 mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="88"/>
                  <measurement group_id="O3" value="83"/>
                  <measurement group_id="O4" value="118"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling &gt; 50 mm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever (defined as axillary temperature equal or above (≥) 37.5 degrees Celsius (°C), gastrointestinal symptoms, which included nausea, vomiting, diarrhoea and/or abdominal pain, headache, myalgia, rash and urticaria. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature ≥ 39 °C. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Related symptom = symptom assessed by the investigator to be causally related to vaccination.</description>
        <time_frame>Within 7 days (Day 0-6) after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="239"/>
                  <measurement group_id="O3" value="238"/>
                  <measurement group_id="O4" value="238"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
            <description>Assessed solicited general symptoms were arthralgia, fatigue, fever (defined as axillary temperature equal or above (≥) 37.5 degrees Celsius (°C), gastrointestinal symptoms, which included nausea, vomiting, diarrhoea and/or abdominal pain, headache, myalgia, rash and urticaria. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature ≥ 39 °C. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Related symptom = symptom assessed by the investigator to be causally related to vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="39"/>
                  <measurement group_id="O4" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="109"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="82"/>
                  <measurement group_id="O3" value="87"/>
                  <measurement group_id="O4" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever (Axillary Temperature &gt;= 37.5°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever (Axillary Temperature &gt;= 39.0°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal Symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal Symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="27"/>
                  <measurement group_id="O4" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal Symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101"/>
                  <measurement group_id="O2" value="116"/>
                  <measurement group_id="O3" value="112"/>
                  <measurement group_id="O4" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="81"/>
                  <measurement group_id="O3" value="91"/>
                  <measurement group_id="O4" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="109"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="87"/>
                  <measurement group_id="O3" value="75"/>
                  <measurement group_id="O4" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies .</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The analysis was performed on the subjects who were administered a 2-dose vaccination schedule.</description>
        <time_frame>At Month 3, 1 month after the second dose of vaccine or placebo</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies .</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The analysis was performed on the subjects who were administered a 2-dose vaccination schedule.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [N=224;204;203]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5844.6" lower_limit="5259.6" upper_limit="6494.7"/>
                  <measurement group_id="O2" value="397.9" lower_limit="337.4" upper_limit="469.2"/>
                  <measurement group_id="O3" value="266.4" lower_limit="227.2" upper_limit="312.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [N=223;206;203]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3543.2" lower_limit="3126.6" upper_limit="4015.3"/>
                  <measurement group_id="O2" value="228.3" lower_limit="196.7" upper_limit="265.0"/>
                  <measurement group_id="O3" value="181.9" lower_limit="156.8" upper_limit="211.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). Groups were stratified into 3 age strata: 9-14, 15-19 and 20-25 years of age at the time of first vaccination. The 15-19 years age stratum in the group receiving the Cervarix vaccine on a 3-dose vaccination schedule was considered an active comparator.</description>
        <time_frame>At Month 7, 1 month after the last dose of vaccine or placebo.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                  <measurement group_id="O2" value="206"/>
                  <measurement group_id="O3" value="204"/>
                  <measurement group_id="O4" value="208"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). Groups were stratified into 3 age strata: 9-14, 15-19 and 20-25 years of age at the time of first vaccination. The 15-19 years age stratum in the group receiving the Cervarix vaccine on a 3-dose vaccination schedule was considered an active comparator.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>9-14 years, Anti-HPV-16 [N=76;62;69;75]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2003.9" lower_limit="1635.7" upper_limit="2455.0"/>
                  <measurement group_id="O2" value="15028.4" lower_limit="12611.3" upper_limit="17908.6"/>
                  <measurement group_id="O3" value="11058.6" lower_limit="9273.8" upper_limit="13186.7"/>
                  <measurement group_id="O4" value="22066.3" lower_limit="18140.7" upper_limit="26841.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-19 years, Anti-HPV-16 [N=72;74;70;66]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1168.5" lower_limit="957.4" upper_limit="1426.2"/>
                  <measurement group_id="O2" value="10818.7" lower_limit="8979.8" upper_limit="13034.2"/>
                  <measurement group_id="O3" value="7869.6" lower_limit="6488.9" upper_limit="9543.9"/>
                  <measurement group_id="O4" value="12817.4" lower_limit="9723.2" upper_limit="16896.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>20-25 years, Anti-HPV-16 [N=73;68;65;67]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1371.2" lower_limit="1092.2" upper_limit="1721.6"/>
                  <measurement group_id="O2" value="7331.4" lower_limit="5965.2" upper_limit="9010.4"/>
                  <measurement group_id="O3" value="5209.2" lower_limit="4166.5" upper_limit="6512.7"/>
                  <measurement group_id="O4" value="7370.0" lower_limit="5673.6" upper_limit="9573.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9-14 years, Anti-HPV-18 [N=76;64;69;75]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1134.3" lower_limit="922.8" upper_limit="1394.3"/>
                  <measurement group_id="O2" value="8085.8" lower_limit="6654.5" upper_limit="9825.0"/>
                  <measurement group_id="O3" value="5630.7" lower_limit="4772.1" upper_limit="6643.7"/>
                  <measurement group_id="O4" value="7192.9" lower_limit="5952.6" upper_limit="8691.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-19 years, Anti-HPV-18 [N=72;74;69;66]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="719.8" lower_limit="571.2" upper_limit="907.0"/>
                  <measurement group_id="O2" value="6170.1" lower_limit="5046.8" upper_limit="7543.5"/>
                  <measurement group_id="O3" value="5039.3" lower_limit="4283.4" upper_limit="5928.5"/>
                  <measurement group_id="O4" value="4907.0" lower_limit="3780.8" upper_limit="6368.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>20-25 years, Anti-HPV-18 [N=72;68;66;67]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="656.5" lower_limit="514.6" upper_limit="837.5"/>
                  <measurement group_id="O2" value="4389.6" lower_limit="3525.6" upper_limit="5465.4"/>
                  <measurement group_id="O3" value="3889.2" lower_limit="2980.9" upper_limit="5074.3"/>
                  <measurement group_id="O4" value="3576.8" lower_limit="2886.5" upper_limit="4432.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 12, at Month 18, at Month 24, at Month 36, and at Month 48 during the safety follow-up phase.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all evaluable subjects eligible for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="216"/>
                  <measurement group_id="O2" value="198"/>
                  <measurement group_id="O3" value="195"/>
                  <measurement group_id="O4" value="198"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 at Month 12 [216;191;195;198]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1064.7" lower_limit="937.5" upper_limit="1209.1"/>
                  <measurement group_id="O2" value="3256.0" lower_limit="2918.8" upper_limit="3632.1"/>
                  <measurement group_id="O3" value="2438.7" lower_limit="2167.2" upper_limit="2744.2"/>
                  <measurement group_id="O4" value="4726.7" lower_limit="4036.8" upper_limit="5534.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 18 [212;196;194;197]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="968.1" lower_limit="845.2" upper_limit="1109.0"/>
                  <measurement group_id="O2" value="2229.4" lower_limit="1983.2" upper_limit="2506.2"/>
                  <measurement group_id="O3" value="1659.1" lower_limit="1466.9" upper_limit="1876.4"/>
                  <measurement group_id="O4" value="3185.1" lower_limit="2735.1" upper_limit="3709.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 24 [199;184;186;190]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="821.2" lower_limit="718.5" upper_limit="938.5"/>
                  <measurement group_id="O2" value="1756.4" lower_limit="1556.6" upper_limit="1981.9"/>
                  <measurement group_id="O3" value="1285.1" lower_limit="1139.6" upper_limit="1449.2"/>
                  <measurement group_id="O4" value="2425.9" lower_limit="2071.1" upper_limit="2841.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 36 [166;158;162;153]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="688.3" lower_limit="592.2" upper_limit="799.9"/>
                  <measurement group_id="O2" value="1462.2" lower_limit="1288.8" upper_limit="1658.8"/>
                  <measurement group_id="O3" value="1094.0" lower_limit="961.1" upper_limit="1245.1"/>
                  <measurement group_id="O4" value="2195.4" lower_limit="1850.8" upper_limit="2604.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 48 [160;151;157;148]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="649.5" lower_limit="556.0" upper_limit="758.8"/>
                  <measurement group_id="O2" value="1261.2" lower_limit="1106.4" upper_limit="1437.7"/>
                  <measurement group_id="O3" value="953.5" lower_limit="835.5" upper_limit="1088.2"/>
                  <measurement group_id="O4" value="1892.3" lower_limit="1594.2" upper_limit="2246.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 12 [215;193;194;198]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="472.9" lower_limit="410.5" upper_limit="544.8"/>
                  <measurement group_id="O2" value="1760.1" lower_limit="1531.5" upper_limit="2022.8"/>
                  <measurement group_id="O3" value="1426.2" lower_limit="1250.8" upper_limit="1626.1"/>
                  <measurement group_id="O4" value="1714.5" lower_limit="1469.7" upper_limit="2000.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 18 [211;198;193;197]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="389.2" lower_limit="338.7" upper_limit="447.2"/>
                  <measurement group_id="O2" value="1025.2" lower_limit="889.0" upper_limit="1182.2"/>
                  <measurement group_id="O3" value="883.1" lower_limit="774.7" upper_limit="1006.8"/>
                  <measurement group_id="O4" value="1096.6" lower_limit="939.4" upper_limit="1280.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 24 [198;186;185;190]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="345.9" lower_limit="299.3" upper_limit="399.8"/>
                  <measurement group_id="O2" value="818.2" lower_limit="706.5" upper_limit="947.5"/>
                  <measurement group_id="O3" value="674.6" lower_limit="591.8" upper_limit="769.0"/>
                  <measurement group_id="O4" value="866.8" lower_limit="741.2" upper_limit="1013.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 36 [166;160;162;153]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="302.2" lower_limit="254.9" upper_limit="358.2"/>
                  <measurement group_id="O2" value="712.8" lower_limit="605.4" upper_limit="839.3"/>
                  <measurement group_id="O3" value="617.9" lower_limit="532.3" upper_limit="717.2"/>
                  <measurement group_id="O4" value="874.2" lower_limit="734.9" upper_limit="1040.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 48 [160;153;157;148]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="260.4" lower_limit="218.5" upper_limit="310.2"/>
                  <measurement group_id="O2" value="626.3" lower_limit="531.0" upper_limit="738.7"/>
                  <measurement group_id="O3" value="517.0" lower_limit="446.2" upper_limit="599.1"/>
                  <measurement group_id="O4" value="723.2" lower_limit="607.2" upper_limit="861.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 7, 1 month after the last dose of vaccine or placebo.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="204"/>
                  <measurement group_id="O4" value="208"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [N=221;204;204;208]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1483.0" lower_limit="1311.0" upper_limit="1677.5"/>
                  <measurement group_id="O2" value="10500.9" lower_limit="9356.9" upper_limit="11784.8"/>
                  <measurement group_id="O3" value="7741.6" lower_limit="6868.2" upper_limit="8726.1"/>
                  <measurement group_id="O4" value="13045.3" lower_limit="11211.4" upper_limit="15179.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [N=220;206;204;208]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="817.3" lower_limit="715.6" upper_limit="933.4"/>
                  <measurement group_id="O2" value="5997.5" lower_limit="5310.9" upper_limit="6772.8"/>
                  <measurement group_id="O3" value="4811.4" lower_limit="4282.7" upper_limit="5405.3"/>
                  <measurement group_id="O4" value="5087.1" lower_limit="4460.2" upper_limit="5802.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents BAS results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="223"/>
                  <measurement group_id="O2" value="221"/>
                  <measurement group_id="O3" value="221"/>
                  <measurement group_id="O4" value="225"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents BAS results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS, PRE NORMAL [N=222;219;218;220], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="219"/>
                  <measurement group_id="O2" value="214"/>
                  <measurement group_id="O3" value="208"/>
                  <measurement group_id="O4" value="214"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE NORMAL [N=222;219;218;220], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE NORMAL [N=222;219;218;220], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE NORMAL [N=222;219;218;220], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE BELOW [N=0;0;1;1], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE BELOW [N=0;0;1;1], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE BELOW [N=0;0;1;1], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE ABOVE [N=1;2;2;4], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE ABOVE [N=1;2;2;4], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, PRE ABOVE [N=1;2;2;4], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range.This outcome presents CREA results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="225"/>
                  <measurement group_id="O3" value="228"/>
                  <measurement group_id="O4" value="229"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range.This outcome presents CREA results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CREA, PRE NORMAL [N=215;211;215;218], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="202"/>
                  <measurement group_id="O2" value="200"/>
                  <measurement group_id="O3" value="210"/>
                  <measurement group_id="O4" value="206"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE NORMAL [N=215;211;215;218], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE NORMAL [N=215;211;215;218], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE NORMAL [N=215;211;215;218], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE BELOW [N=8;7;7;6], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE BELOW [N=8;7;7;6], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE BELOW [N=8;7;7;6], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE BELOW [N=8;7;7;6], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE ABOVE [N=3;7;6;5], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE ABOVE [N=3;7;6;5], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, PRE ABOVE [N=3;7;6;5], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents EOS results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="223"/>
                  <measurement group_id="O3" value="223"/>
                  <measurement group_id="O4" value="226"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents EOS results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>EOS, PRE NORMAL [N=209;214;212;214], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="207"/>
                  <measurement group_id="O3" value="200"/>
                  <measurement group_id="O4" value="205"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE NORMAL [N=209;214;212;214], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE NORMAL [N=209;214;212;214], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE NORMAL [N=209;214;212;214], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE BELOW [N=1;2;1;0], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE BELOW [N=1;2;1;0], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE BELOW [N=1;2;1;0], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE ABOVE [N=16;7;10;12], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE ABOVE [N=16;7;10;12], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE ABOVE [N=16;7;10;12], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, PRE ABOVE [N=16;7;10;12], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents Hct results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="229"/>
                  <measurement group_id="O2" value="228"/>
                  <measurement group_id="O3" value="227"/>
                  <measurement group_id="O4" value="233"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents Hct results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hct, PRE NORMAL [N=215;208;208;217], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="196"/>
                  <measurement group_id="O2" value="193"/>
                  <measurement group_id="O3" value="189"/>
                  <measurement group_id="O4" value="208"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE NORMAL [N=215;208;208;217], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE NORMAL [N=215;208;208;217], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE NORMAL [N=215;208;208;217], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE BELOW [N=6;7;7;3], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE BELOW [N=6;7;7;3], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE BELOW [N=6;7;7;3], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE ABOVE [N=8;13;12;13], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE ABOVE [N=8;13;12;13], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct, PRE ABOVE [N=8;13;12;13], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents ALT results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="229"/>
                  <measurement group_id="O2" value="227"/>
                  <measurement group_id="O3" value="229"/>
                  <measurement group_id="O4" value="233"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents ALT results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT, PRE NORMAL [N=215;219;225;218], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="211"/>
                  <measurement group_id="O2" value="211"/>
                  <measurement group_id="O3" value="213"/>
                  <measurement group_id="O4" value="209"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE NORMAL [N=215;219;225;218], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE NORMAL [N=215;219;225;218], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE NORMAL [N=215;219;225;218], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE BELOW [N=1;3;1;4], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE BELOW [N=1;3;1;4], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE BELOW [N=1;3;1;4], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE ABOVE [N=13;5;3;11], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE ABOVE [N=13;5;3;11], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE ABOVE [N=13;5;3;11], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, PRE ABOVE [N=13;5;3;11], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents LYM results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="223"/>
                  <measurement group_id="O3" value="223"/>
                  <measurement group_id="O4" value="227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents LYM results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>LYM, PRE NORMAL [N=211;211;204;213], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="202"/>
                  <measurement group_id="O3" value="192"/>
                  <measurement group_id="O4" value="202"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE NORMAL [N=211;211;204;213], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE NORMAL [N=211;211;204;213], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE NORMAL [N=211;211;204;213], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE BELOW [N=6;3;5;5], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE BELOW [N=6;3;5;5], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE BELOW [N=6;3;5;5], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE ABOVE [N=9;9;14;9], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE ABOVE [N=9;9;14;9], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, PRE ABOVE [N=9;9;14;9], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents MON results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="223"/>
                  <measurement group_id="O3" value="223"/>
                  <measurement group_id="O4" value="227"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents MON results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>MON, PRE NORMAL [N=217;211;211;219], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="202"/>
                  <measurement group_id="O3" value="197"/>
                  <measurement group_id="O4" value="208"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE NORMAL [N=217;211;211;219], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE NORMAL [N=217;211;211;219], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE NORMAL [N=217;211;211;219], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE BELOW [N=3;2;0;2], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE BELOW [N=3;2;0;2], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE BELOW [N=3;2;0;2], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE ABOVE [N=6;10;12;6], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE ABOVE [N=6;10;12;6], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE ABOVE [N=6;10;12;6], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, PRE ABOVE [N=6;10;12;6], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents NEU results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                  <measurement group_id="O2" value="223"/>
                  <measurement group_id="O3" value="223"/>
                  <measurement group_id="O4" value="226"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents NEU results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>NEU, PRE NORMAL [N=206;207;202;204], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="188"/>
                  <measurement group_id="O3" value="185"/>
                  <measurement group_id="O4" value="186"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE NORMAL [N=206;207;202;204], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE NORMAL [N=206;207;202;204], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE NORMAL [N=206;207;202;204], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE BELOW [N=11;11;16;19], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE BELOW [N=11;11;16;19], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE BELOW [N=11;11;16;19], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE ABOVE [N=7;5;5;3], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE ABOVE [N=7;5;5;3], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE ABOVE [N=7;5;5;3], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, PRE BELOW [N=11;11;16;19], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents RBC results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="229"/>
                  <measurement group_id="O2" value="228"/>
                  <measurement group_id="O3" value="228"/>
                  <measurement group_id="O4" value="233"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents RBC results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>RBC, PRE NORMAL [N=214;215;204;225], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="196"/>
                  <measurement group_id="O4" value="213"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE NORMAL [N=214;215;204;225], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE NORMAL [N=214;215;204;225], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE NORMAL [N=214;215;204;225], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE BELOW [N=6;6;12;4], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE BELOW [N=6;6;12;4], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE BELOW [N=6;6;12;4], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE ABOVE [N=9;7;12;4], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE ABOVE [N=9;7;12;4], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, PRE ABOVE [N=9;7;12;4], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents WBC results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="229"/>
                  <measurement group_id="O2" value="228"/>
                  <measurement group_id="O3" value="229"/>
                  <measurement group_id="O4" value="233"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents WBC results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>WBC, PRE NORMAL [N=207;213;211;225], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="197"/>
                  <measurement group_id="O2" value="199"/>
                  <measurement group_id="O3" value="194"/>
                  <measurement group_id="O4" value="212"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE NORMAL [N=207;213;211;225], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE NORMAL [N=207;213;211;225], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE NORMAL [N=207;213;211;225], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE BELOW [N=8;9;6;4], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE BELOW [N=8;9;6;4], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE BELOW [N=8;9;6;4], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE ABOVE [N=14;6;12;4], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE ABOVE [N=14;6;12;4], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, PRE ABOVE [N=14;6;12;4], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
        <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents PLA results.</description>
        <time_frame>At Month 7 (M7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Analysis for this outcome was done on subjects with available results for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="227"/>
                  <measurement group_id="O3" value="228"/>
                  <measurement group_id="O4" value="232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Laboratory Parameters Assessed.</title>
            <description>Assessed parameters were alanine aminotransferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocritis (Hct), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). Subjects were categorized according to their results at pre-vaccination at Month 0 (PRE) which were normal, above normal or below the normal range. Per parameter and range, it was assessed whether laboratory values of the subjects were normal, above normal or below the normal range. This outcome presents PLA results.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>PLA, PRE NORMAL [N=211;210;215;221], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="206"/>
                  <measurement group_id="O4" value="218"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE NORMAL [N=211;210;215;221], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE NORMAL [N=211;210;215;221], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE NORMAL [N=211;210;215;221], M7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE BELOW [N=0;3;0;3], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE BELOW [N=0;3;0;3], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE BELOW [N=0;3;0;3], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE ABOVE [N=15;14;13;8], M7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE ABOVE [N=15;14;13;8], M7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, PRE ABOVE [N=15;14;13;8], M7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against Human Papillomavirus 16 (HPV-16) and Human Papillomavirus 18 (HPV-18)</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e.titers greater than or equal to (≥) cut-off value) in the serum of subjects seronegative before vaccination. Assay cut-off was defined as ≥ 8 ELISA units per milliliter (EL.U/mL) for HPV-16, and 7 EL.U/mL for HPV-18. Seronegative subjects are subjects who had an antibody concentration below cut-off value. Cut-off values were 8 EL.U/mL for antibody concentrations against HPV-16, and 7 EL.U/mL for antibody concentrations against HPV-18.</description>
        <time_frame>At Month 12, at Month 18, at Month 24, at Month 36, and at Month 48 during the safety follow-up phase.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="216"/>
                  <measurement group_id="O2" value="196"/>
                  <measurement group_id="O3" value="195"/>
                  <measurement group_id="O4" value="198"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against Human Papillomavirus 16 (HPV-16) and Human Papillomavirus 18 (HPV-18)</title>
            <description>Seroconversion was defined as the appearance of antibodies (i.e.titers greater than or equal to (≥) cut-off value) in the serum of subjects seronegative before vaccination. Assay cut-off was defined as ≥ 8 ELISA units per milliliter (EL.U/mL) for HPV-16, and 7 EL.U/mL for HPV-18. Seronegative subjects are subjects who had an antibody concentration below cut-off value. Cut-off values were 8 EL.U/mL for antibody concentrations against HPV-16, and 7 EL.U/mL for antibody concentrations against HPV-18.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 at Month 12 [N=216;191;195;198]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="194"/>
                  <measurement group_id="O2" value="162"/>
                  <measurement group_id="O3" value="172"/>
                  <measurement group_id="O4" value="169"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 18 [N=212;196;194;197]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                  <measurement group_id="O2" value="166"/>
                  <measurement group_id="O3" value="172"/>
                  <measurement group_id="O4" value="168"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 24 [N=199;184;186;190]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="185"/>
                  <measurement group_id="O2" value="155"/>
                  <measurement group_id="O3" value="165"/>
                  <measurement group_id="O4" value="162"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 36 [N=166;158;162;153]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="135"/>
                  <measurement group_id="O3" value="146"/>
                  <measurement group_id="O4" value="135"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 at Month 48 [N=160;151;157;148]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="130"/>
                  <measurement group_id="O3" value="139"/>
                  <measurement group_id="O4" value="129"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 12 [N=215;193;194;198]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="187"/>
                  <measurement group_id="O2" value="173"/>
                  <measurement group_id="O3" value="166"/>
                  <measurement group_id="O4" value="173"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 18 [N=211;198;193;197]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="177"/>
                  <measurement group_id="O3" value="166"/>
                  <measurement group_id="O4" value="173"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 24 [N=198;186;185;190]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="173"/>
                  <measurement group_id="O2" value="165"/>
                  <measurement group_id="O3" value="159"/>
                  <measurement group_id="O4" value="166"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 36 [N=166;160;162;153]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="139"/>
                  <measurement group_id="O4" value="132"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 48 [N=160;153;157;148]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                  <measurement group_id="O2" value="139"/>
                  <measurement group_id="O3" value="135"/>
                  <measurement group_id="O4" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The assay cut-off for Month 60 was defined as ≥ 19 ELISA units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 60 of the safety follow-up phase</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="134"/>
                  <measurement group_id="O3" value="131"/>
                  <measurement group_id="O4" value="146"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). The assay cut-off for Month 60 was defined as ≥ 19 ELISA units per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 at Month 60 [N=137;132;131;146]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="658.0" lower_limit="560.4" upper_limit="772.5"/>
                  <measurement group_id="O2" value="1254.0" lower_limit="1088.5" upper_limit="1444.8"/>
                  <measurement group_id="O3" value="976.1" lower_limit="846.1" upper_limit="1126.1"/>
                  <measurement group_id="O4" value="1858.5" lower_limit="1586.2" upper_limit="2177.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 60 [N=137;134;131;146]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="269.4" lower_limit="223.0" upper_limit="325.5"/>
                  <measurement group_id="O2" value="622.2" lower_limit="519.0" upper_limit="745.9"/>
                  <measurement group_id="O3" value="557.9" lower_limit="473.7" upper_limit="657.0"/>
                  <measurement group_id="O4" value="745.3" lower_limit="629.3" upper_limit="882.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against Human Papillomavirus 16 (HPV-16) and Human Papillomavirus 18 (HPV-18)</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e. titers greater than or equal to (≥) cut-off value) in the serum of subjects seronegative before vaccination. Assay cut-off was defined as ≥ 19 ELISA units per milliliter (EL.U/mL). Seronegative subjects are subjects who had an antibody concentration below cut-off value.</description>
        <time_frame>At Month 60 of the safety follow-up phase</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the ATP cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="119"/>
                  <measurement group_id="O4" value="127"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against Human Papillomavirus 16 (HPV-16) and Human Papillomavirus 18 (HPV-18)</title>
            <description>Seroconversion was defined as the appearance of antibodies (i.e. titers greater than or equal to (≥) cut-off value) in the serum of subjects seronegative before vaccination. Assay cut-off was defined as ≥ 19 ELISA units per milliliter (EL.U/mL). Seronegative subjects are subjects who had an antibody concentration below cut-off value.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 at Month 60 [N=130;114;119;127]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="114"/>
                  <measurement group_id="O3" value="119"/>
                  <measurement group_id="O4" value="127"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 at Month 60 [N=117;122;116;125]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="116"/>
                  <measurement group_id="O2" value="122"/>
                  <measurement group_id="O3" value="116"/>
                  <measurement group_id="O4" value="125"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancy Outcomes.</title>
        <description>Pregnancy outcomes were ectopic pregnancy, elective termination with no apparent congenital anomaly (ACA), elective termination with congenital anomaly (CA), lost to follow up, pregnancy ongoing, spontaneous abortion with no ACA and live infant with no ACA.</description>
        <time_frame>From Month 0 to Month 48.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on pregnant subjects in the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Pregnancy Outcomes.</title>
            <description>Pregnancy outcomes were ectopic pregnancy, elective termination with no apparent congenital anomaly (ACA), elective termination with congenital anomaly (CA), lost to follow up, pregnancy ongoing, spontaneous abortion with no ACA and live infant with no ACA.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ectopic pregnancy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination with NO ACA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination with CA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Live infant with NO ACA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lost to follow up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pregnancy ongoing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spontaneous abortion with NO ACA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancy Outcomes.</title>
        <description>Pregnancy outcomes were ectopic pregnancy, elective termination with no apparent congenital anomaly (ACA), elective termination with congenital anomaly (CA), lost to follow up, pregnancy ongoing, spontaneous abortion with no ACA and live infant with no ACA.</description>
        <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on pregnant subjects in the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Pregnancy Outcomes.</title>
            <description>Pregnancy outcomes were ectopic pregnancy, elective termination with no apparent congenital anomaly (ACA), elective termination with congenital anomaly (CA), lost to follow up, pregnancy ongoing, spontaneous abortion with no ACA and live infant with no ACA.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ectopic pregnancy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination NO apparent congenital anom.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination congenital anomaly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Live infant NO apparent congenital anomaly</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lost to follow up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Molar pregnancy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spontaneous abortion NO apparent congenital anom.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event (AE) is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = an event that prevented normal activity. Related = an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 30 days (Day 0-29) after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
            <description>An unsolicited adverse event (AE) is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = an event that prevented normal activity. Related = an event assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any unsolicited AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="85"/>
                  <measurement group_id="O3" value="76"/>
                  <measurement group_id="O4" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 unsolicited AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related unsolicited AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
        <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
        <time_frame>From Month 0 to Month 7.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
            <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="48"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
        <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
        <time_frame>From Month 0 to Month 48.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
            <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="94"/>
                  <measurement group_id="O3" value="88"/>
                  <measurement group_id="O4" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
        <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
        <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
            <description>MSCs were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. The following did not require reporting as long as they were not considered SAEs and occurred more than 30 days after each vaccination: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities, injury, visits for routine physical examination or visits for vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="97"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Autoimmune Diseases (NOADs)</title>
        <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
        <time_frame>From Month 0 to Month 7.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Autoimmune Diseases (NOADs)</title>
            <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Autoimune Diseases (NOADs)</title>
        <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
        <time_frame>From Month 0 to Month 48.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Autoimune Diseases (NOADs)</title>
            <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Autoimmune Diseases (NOADs)</title>
        <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
        <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Autoimmune Diseases (NOADs)</title>
            <description>NOADs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</title>
        <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
        <time_frame>From Month 0 to Month 7.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</title>
            <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</title>
        <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
        <time_frame>From Month 0 to Month 48.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</title>
            <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</title>
        <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
        <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs)</title>
            <description>NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity, or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 0 to Month 7.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity, or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 0 to Month 48.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Throughout the study period, from Month 0 to Month 60.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1/Placebo Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
            <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Cervarix 2 Group</title>
            <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="240"/>
                  <measurement group_id="O2" value="241"/>
                  <measurement group_id="O3" value="240"/>
                  <measurement group_id="O4" value="239"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events: From Month 0 to Month 60. Unsolicited adverse events: Within the 30-day (Days 0-29) follow-up period after vaccination. Solicited symptoms: Within the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
      <desc>3 among the serious adverse events (SAEs) listed below are SAEs reported for the subject’s offsprings (Spina bifida, Foetal distress syndrome and Premature baby).</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix 1/Placebo Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix 1/Placebo/Cervarix 1 Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Cervarix 2/Placebo/Cervarix 2 Group</title>
          <description>Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Cervarix 2 Group</title>
          <description>Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Spina bifida</sub_title>
                <description>SAE reported for the subject’s offspring</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ligament laxity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basilar artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <description>SAE reported for the subject’s offspring</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <description>SAE reported for the subject’s offspring</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Bulimia nervosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="222" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="225" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="222" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="225" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="145" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="125" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>If appropriate, describe significant limitations of the trial. Examples: Early termination leading to small number of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
